Genscript Biotech Corporation (G51) — Cash Flow Reinvestment Rate
Genscript Biotech Corporation (G51) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting €0.00 (capex €0.00 ) from operating cash flow of €61.62 Million. Explore G51 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Genscript Biotech Corporation Cash Flow Reinvestment Rate (2016–2025)
Historical reinvestment intensity for Genscript Biotech Corporation across 5 annual periods. Also explore Genscript Biotech Corporation asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Genscript Biotech Corporation (2016–2025)
Year-by-year capital reinvestment analysis for Genscript Biotech Corporation. For live market cap and broader valuation context, see Genscript Biotech Corporation (G51) total market value.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | €147.45 Million | €325.52 Million | €83.84 Million | ▼ -96.4% |
| 2024 | 12.49x | €945.21 Million | €75.65 Million | €147.92 Million | ▲ +2502.3% |
| 2018 | 0.48x | €147.72 Million | €307.66 Million | €70.84 Million | ▼ -69.9% |
| 2017 | 1.60x | €34.09 Million | €21.37 Million | €29.21 Million | ▲ +206.9% |
| 2016 | 0.52x | €17.30 Million | €33.27 Million | €8.98 Million | — |